Detailed Analysis of the Pulsations During and After Bursts from the Bursting Pulsar (GRO J1744-28)

The hard X-ray bursts observed during both major outbursts of the Bursting Pulsar (GRO J1744-28) show pulsations near the neutron star spin frequency with an enhanced amplitude relative to that of the persistent emission. Consistent with previous work, we find that the pulsations within bursts lag behind their expected arrival times based upon the persistent pulsar ephemeris. For an ensemble of 1293 bursts recorded with the Burst and Transient Source Experiment, the average burst pulse time delay is 61.0 +/- 0.8 ms in the 25 - 50 keV energy range and 72 +/- 5 ms in the 50 - 100 keV band. The residual time delay from 10 to 240 s following the start of the burst is 18.1 +/- 0.7 ms (25 - 50 keV). A significant correlation of the average burst time delay with burst peak flux is found. Our results are consistent with the model of the pulse time lags presented by Miller (1996).Comment: 11 pages, accepted for publication in Ap

Statistical properties of SGR 1900+14 bursts

We study the statistics of soft gamma repeater (SGR) bursts, using a data base of 187 events detected with BATSE and 837 events detected with RXTE PCA, all from SGR 1900+14 during its 1998-1999 active phase. We find that the fluence or energy distribution of bursts is consistent with a power law of index 1.66, over 4 orders of magnitude. This scale-free distribution resembles the Gutenberg-Richter Law for earthquakes, and gives evidence for self-organized criticality in SGRs. The distribution of time intervals between successive bursts from SGR 1900+14 is consistent with a log-normal distribution. There is no correlation between burst intensity and the waiting times till the next burst, but there is some evidence for a correlation between burst intensity and the time elapsed since the previous burst. We also find a correlation between the duration and the energy of the bursts, but with significant scatter. In all these statistical properties, SGR bursts resemble earthquakes and solar flares more closely than they resemble any known accretion-powered or nuclear-powered phenomena. Thus our analysis lends support to the hypothesis that the energy source for SGR bursts is internal to the neutron star, and plausibly magnetic.Comment: 11 pages, 4 figures, accepted for publication in ApJ

Memetic Perspectives on the Evolution of Tonal Systems

Cohn (1996) and Taruskin (1985) consider the increasing prominence during the nineteenth century of harmonic progressions derived from the hexatonic and octatonic pitch collections respectively. This development is clearly evident in music of the third quarter of the century onwards and is a consequence of forces towards non-diatonic organization latent in earlier music. This article conceptualizes such forces as memetic — drawing a distinction between memetic processes in music itself and those in the realm of music theory — and interprets the gradualistic evolution of tonal systems as one of their most significant consequences. After outlining hypotheses for the mechanisms driving such evolution, it identifies a number of ‘musemes’ implicated in hexatonic and octatonic organization in a passage from Mahler’s Symphony no. 10. Pople’s (2002) Tonalities music-analysis software is used to explore the tonal organization of the passage, which is considered in relation to the musemes hypothesized to generate and underpin it

Simultaneous Measurements of X-Ray Luminosity and Kilohertz Quasi-Periodic Oscillations in Low-Mass X-Ray Binaries

We measure simultaneously the properties of the energy spectra and the frequencies of the kilohertz quasi-periodic oscillations (QPOs) in fifteen low mass X-ray binaries covering a wide range of X-ray luminosities. In each source the QPO frequencies cover the same range of approximately 300 Hz to 1300 Hz, though the sources differ by two orders of magnitude in their X-ray luminosities (as measured from the unabsorbed 2-50 keV flux). So the X-ray luminosity does not uniquely determine the QPO frequency. This is difficult to understand since the evidence from individual sources indicates that the frequency and luminosity are very well correlated at least over short timescales. Perhaps beaming effects or bolometric corrections change the observed luminosities, or perhaps part of the energy in mass accretion is used to power outflows reducing the energy emitted in X-rays. It is also possible that the parameters of a QPO model are tuned in such a way that the same range of frequencies appears in all sources. Different modes of accretion may be involved for example (disk and radial) or multiple parameters may conspire to yield the same frequencies.Comment: 14 pages, 2 figures (1 in color), accepted by ApJ, see the 'QPO page': http://www.astro.uva.nl/~ecford/qpos.htm

Identification of a Likely Radio Counterpart of the Rapid Burster

We have identified a likely radio counterpart to the low-mass X-ray binary MXB 1730-335 (the Rapid Burster). The counterpart has shown 8.4 GHz radio on/off behavior correlated with the X-ray on/off behavior as observed by the RXTE/ASM during six VLA observations. The probability of an unrelated, randomly varying background source duplicating this behavior is 1-3% depending on the correlation time scale. The location of the radio source is RA 17h 33m 24.61s; Dec -33d 23' 19.8" (J2000), +/- 0.1". We do not detect 8.4 GHz radio emission coincident with type II (accretion-driven) X-ray bursts. The ratio of radio to X-ray emission during such bursts is constrained to be below the ratio observed during X-ray persistent emission at the 2.9-sigma level. Synchrotron bubble models of the radio emission can provide a reasonable fit to the full data set, collected over several outbursts, assuming that the radio evolution is the same from outburst to outburst, but given the physical constraints the emission is more likely to be due to ~hour-long radio flares such as have been observed from the X-ray binary GRS 1915+105.Comment: 28 pages, 4 figures; accepted for publication in ApJ (no changes

Permeable conformal walls and holography

We study conformal field theories in two dimensions separated by domain walls, which preserve at least one Virasoro algebra. We develop tools to study such domain walls, extending and clarifying the concept of `folding' discussed in the condensed-matter literature. We analyze the conditions for unbroken supersymmetry, and discuss the holographic duals in AdS3 when they exist. One of the interesting observables is the Casimir energy between a wall and an anti-wall. When these separate free scalar field theories with different target-space radii, the Casimir energy is given by the dilogarithm function of the reflection probability. The walls with holographic duals in AdS3 separate two sigma models, whose target spaces are moduli spaces of Yang-Mills instantons on T4 or K3. In the supergravity limit, the Casimir energy is computable as classical energy of a brane that connects the walls through AdS3. We compare this result with expectations from the sigma-model point of view.Comment: Latex file, 34 pages, 8 figures, uses JHEP3.cls. Typos corrected and references adde

Are vaccination programmes delivered by lay health workers cost-effective? A systematic review

<p>Abstract</p> <p>Background</p> <p>A recently updated Cochrane systematic review on the effects of lay or community health workers (LHWs) in primary and community health care concluded that LHW interventions could lead to promising benefits in the promotion of childhood vaccination uptake. However, understanding of the costs and cost-effectiveness of involving LHWs in vaccination programmes remains poor. This paper reviews the costs and cost-effectiveness of vaccination programme interventions involving LHWs.</p> <p>Methods</p> <p>Articles were retrieved if the title, keywords or abstract included terms related to 'lay health workers', 'vaccination' and 'economics'. Reference lists of studies assessed for inclusion were also searched and attempts were made to contact authors of all studies included in the Cochrane review. Studies were included after assessing eligibility of the full-text article. The included studies were then reviewed against a set of background and technical characteristics.</p> <p>Results</p> <p>Of the 2616 records identified, only three studies fully met the inclusion criteria, while an additional 11 were retained as they included some cost data. Methodologically, the studies were strong but did not adequately address affordability and sustainability and were also highly heterogeneous in terms of settings and LHW outcomes, limiting their comparability. There were insufficient data to allow any conclusions to be drawn regarding the cost-effectiveness of LHW interventions to promote vaccination uptake. Studies focused largely on health outcomes and did illustrate to some extent how the institutional characteristics of communities, such as governance and sources of financial support, influence sustainability.</p> <p>Conclusion</p> <p>The included studies suggest that conventional economic evaluations, particularly cost-effectiveness analyses, generally focus too narrowly on health outcomes, especially in the context of vaccination promotion and delivery at the primary health care level by LHWs. Further studies on the costs and cost-effectiveness of vaccination programmes involving LHWs should be conducted, and these studies should adopt a broader and more holistic approach.</p

D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data

Importance: Whether and under which conditions D-cycloserine (DCS) augments the effects of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders is unclear. Objective: To clarify whether DCS is superior to placebo in augmenting the effects of cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders and to evaluate whether antidepressants interact with DCS and the effect of potential moderating variables. Data Sources: PubMed, EMBASE, and PsycINFO were searched from inception to February 10, 2016. Reference lists of previous reviews and meta-analyses and reports of randomized clinical trials were also checked. Study Selection: Studies were eligible for inclusion if they were (1) double-blind randomized clinical trials of DCS as an augmentation strategy for exposure-based cognitive behavior therapy and (2) conducted in humans diagnosed as having specific phobia, social anxiety disorder, panic disorder with or without agoraphobia, obsessive-compulsive disorder, or posttraumatic stress disorder. Data Extraction and Synthesis: Raw data were obtained from the authors and quality controlled. Data were ranked to ensure a consistent metric across studies (score range, 0-100). We used a 3-level multilevel model nesting repeated measures of outcomes within participants, who were nested within studies. Results: Individual participant data were obtained for 21 of 22 eligible trials, representing 1047 of 1073 eligible participants. When controlling for antidepressant use, participants receiving DCS showed greater improvement from pretreatment to posttreatment (mean difference, -3.62; 95% CI, -0.81 to -6.43; P = .01; d = -0.25) but not from pretreatment to midtreatment (mean difference, -1.66; 95% CI, -4.92 to 1.60; P = .32; d = -0.14) or from pretreatment to follow-up (mean difference, -2.98, 95% CI, -5.99 to 0.03; P = .05; d = -0.19). Additional analyses showed that participants assigned to DCS were associated with lower symptom severity than those assigned to placebo at posttreatment and at follow-up. Antidepressants did not moderate the effects of DCS. None of the prespecified patient-level or study-level moderators was associated with outcomes. Conclusions and Relevance: D-cycloserine is associated with a small augmentation effect on exposure-based therapy. This effect is not moderated by the concurrent use of antidepressants. Further research is needed to identify patient and/or therapy characteristics associated with DCS response.2018-05-0

The Wooster Voice (Wooster, OH), 1949-12-08

Dr. T. Cuyler Young addresses the campus during the annual Wooster Day celebration. Dr. Delbert Lean will give his 40th annual reading of Charles Dickens\u27 Christmas Carol. Plans to build a darkroom for student publications are announced. Additionally, Wooster host the fall conference of the Ohio division of the National Student Association.https://openworks.wooster.edu/voice1941-1950/1204/thumbnail.jp

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence:the randomized phase 2a TITAN trial

Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double-blinded trial, 43 people (85% males) with HIV-1 on ART were randomized to (1) placebo/placebo, (2) lefitolimod (TLR9 agonist)/placebo, (3) placebo/broadly neutralizing anti-HIV-1 antibodies (bNAbs) or (4) lefitolimod/bNAb. ART interruption (ATI) started at week 3. Lefitolimod was administered once weekly for the first 8 weeks, and bNAbs were administered twice, 1 d before and 3 weeks after ATI. The primary endpoint was time to loss of virologic control after ATI. The median delay in time to loss of virologic control compared to the placebo/placebo group was 0.5 weeks (P = 0.49), 12.5 weeks (P = 0.003) and 9.5 weeks (P = 0.004) in the lefitolimod/placebo, placebo/bNAb and lefitolimod/bNAb groups, respectively. Among secondary endpoints, viral doubling time was slower for bNAb groups compared to non-bNAb groups, and the interventions were overall safe. We observed no added benefit of lefitolimod. Despite subtherapeutic plasma bNAb levels, 36% (4/11) in the placebo/bNAb group compared to 0% (0/10) in the placebo/placebo group maintained virologic control after the 25-week ATI. Although immunotherapy with lefitolimod did not lead to ART-free HIV-1 control, bNAbs may be important components in future HIV-1 curative strategies. ClinicalTrials.gov identifier: NCT03837756 .</p